Regenxbio RGNX Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $15.23M-55.8% | $34.47M-41.4% | $58.8M-26.1% | $79.56M-38.9% | $130.1M+126% | ||
| $135.26M-30.8% | $195.6M-9.2% | $215.4M-11.6% | $243.74M+76.9% | $137.77M-22.2% | ||
| $10.04M-61.9% | $26.38M+4.1% | $25.35M+25.5% | $20.2M+11.0% | $18.19M-11.1% | ||
| $186.52M-33.7% | $281.28M-15.3% | $331.97M-11.2% | $373.75M+19.3% | $313.24M+12.7% | ||
| $101.87M-2.8% | $104.86M-2.5% | $107.52M-3.2% | $111.02M-3.0% | $114.5M-2.6% | ||
| $341.89M-24.5% | $453.03M-13.7% | $525.2M-9.6% | $581.03M+18.4% | $490.93M+5.4% | ||
| $21.21M-0.7% | $21.36M-4.1% | $22.27M+2.8% | $21.66M+13.7% | $19.04M-16.5% | ||
| $5.92M-43.4% | $10.45M-20.8% | $13.2M-5.6% | $13.98M+2.9% | $13.59M+11,716% | ||
| $71.11M-39.8% | $118.1M-5.2% | $124.57M+4.2% | $119.54M+12.0% | $106.73M+3.4% | ||
| $320.81M-8.4% | $350.3M-3.7% | $363.75M-1.0% | $367.35M+69.5% | $216.73M+5.0% | ||
| $5K0.0% | $5K0.0% | $5K0.0% | $5K0.0% | $5K0.0% | ||
| -$1.22B-8.0% | -$1.13B-6.3% | -$1.06B-6.2% | -$996.94M-7.7% | -$926.07M+0.7% | ||
| $21.08M-79.5% | $102.73M-36.4% | $161.45M-24.4% | $213.68M-22.1% | $274.2M+5.6% | ||
| $341.89M-24.5% | $453.03M-13.7% | $525.2M-9.6% | $581.03M+18.4% | $490.93M+5.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Regenxbio's total assets?
- Regenxbio (RGNX) holds $341.9M in total assets, down 30.4% year over year.
- How much debt does Regenxbio have?
- Regenxbio carries $71.1M in total debt against $21.1M of shareholders' equity, a debt-to-equity ratio of 3.37.
- How much cash does Regenxbio have?
- Regenxbio holds $15.2M in cash and equivalents.
- Can Regenxbio cover its short-term obligations?
- Its current ratio is 2.62 — current assets exceed current liabilities.
- Where does Regenxbio's balance sheet data come from?
- Every line is extracted from Regenxbio's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
